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1. Introduction
Pregnancy has a profound effect on the thyroid gland and its function. In iodine-replete
countries, the gland size has been found to increase by 10% during pregnancy, and in areas
of iodine deficiency, the gland size increases by 20%–40%. The prevalence of hypothyroid‐
ism during pregnancy is estimated to be 0.3–0.5% for overt hypothyroidism and 2–3% for
subclinical hypothyroidism. Worldwide, iodine deficiency remains one of the leading causes
of both overt and subclinical hypothyroidism. However, there are many other causes of hy‐
pothyroidism during pregnancy, including autoimmune thyroiditis, the most common or‐
ganic pathology [1]. Other causes include the following: thyroid radioiodine ablation (to
treat hyperthyroidism or thyroid cancer), hypoplasia and/or agenesis of the thyroid gland,
surgery (for thyroid tumors and, rarely, central hypothyroidism, including lymphocytic hy‐
pophysitis or ectopic thyroid) and some drugs, such as rifampin and phenytoin, which can
alter thyroid metabolism [2].
It  has long been recognized that  iodine represents an essential  element for fetal  growth
and  development  [3].  In  fact,  congenital  hypothyroidism  leads  to  cretinism,  which  is
characterized  by  irreversible  growth  restriction  and  mental  retardation.  In  mountain
areas,  such as  the  Himalayas,  Alps  and Andes,  iodine  depletion can be  caused by gla‐
ciers and erosion [4],  leading to the presence of cretinism in small sections of the popu‐
lation. Nonetheless,  a significant proportion of the population is exposed to mild iodine
deficiency, which is responsible for the clinical features of defined goiters, impaired cog‐
nition and hypothyroidism [5].  One way to escape the dangerous and hidden deficiency
is to incorporate iodine into the daily diets of people all over the world [6]. Today, as a
result of this strategy, there are no countries with endemic iodine deficiencies,  and only
approximately 32 countries in the world with a public problem of mild to moderate io‐
dine  deficiency  [7].  Some  meta-analyses  have  studied  the  intelligence  quotient  (IQ)  re‐
duction  in  children  who  suffered  from  iodine  deficiency,  but,  due  to  confounding
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factors, it has not been well elucidated whether the IQ reduction depends on an “intra-”
or “extra-” uterine iodine deficiency [8].  However,  some studies have stressed that  cog‐
nitive  disorders  that  are  linked  to  a  mild-moderate  iodine  deficiency  are  a  reversible
clinical  phenomenon  [9-16].  These  considerations  are  interesting  because  recent  data
have  indicated  the  recurrence  of  iodine  deficiency  in  developed  countries,  such  as  the
United  States,  Australia,  New  Zealand,  United  Kingdom  and,  especially,  in  Europe
[17,18].
Given that maternal iodine supplementation has a positive impact on the developmental
quotient  of  children  living  in  areas  of  iodine  deficiency,  the  current  WHO  guidelines
suggest  that  iodized  salt  provides  sufficient  iodine  intake  for  pregnant  women [19].  In
particular,  iodine supplementation is  recommended beginning in early pregnancy to en‐
sure adequate fetal  brain development.  A useful test  to verify sufficient iodine intake is
the  assessment  of  urinary  iodine  concentration.  Thresholds  for  median  urinary  iodine
sufficiency have been identified for populations but not for individuals, given the signif‐
icant  day-to-day  variation  of  iodine  intake  [20].  The  cut-off  for  iodine  sufficiency  is  a
median urinary  iodine  concentration of  100–199  μg/L in  adults  and of  150–249  μg/L in
pregnant  women [21].  However,  in  some areas,  iodine intake is  sufficient  in  schoolchil‐
dren but not in pregnant women. This situation necessitates an additional strategy if  io‐
dized salt is already in use [22]. Some studies analyzing mildly iodine-deficient pregnant
European women revealed that  iodine supplementation is  stopped before or  at  the mo‐
ment  of  delivery  [23].  In  these  patients,  iodine  supplementation  was  observed  to  in‐
crease  maternal  urinary  iodine  excretion  and  reduce  thyroid  volume.  Additionally,  no
alterations in newborn thyroid volumes and no increased thyroglobulin maternal  serum
levels  were  present.  However,  these  studies  only  demonstrate  that  iodine supplementa‐
tion  affects  infant  growth  and  development.  Several  studies  [24-26]  have  attempted  to
analyze the relationship between iodine supplementation and fetal effects, but no signifi‐
cant effects on mental or motor development in the offspring were observed [8].
It is important to emphasize that following delivery, maternal iodine remains the only io‐
dine source for breastfed infants; a breastfeeding woman excretes approximately 75–200 μg
iodine daily in her breast milk [27,28]. Dietary iodine intake during lactation ranges from
250 to 290 μg/day, higher than the 150 μg/day recommended for non-pregnant women and
adults. Adequate breast milk iodine levels are important for normal neurodevelopment in
infants, and iodine supplements are essential for mothers living in iodine deficient areas,
who are unable to meet the increased demands for iodine intake.
In cases of iodine deficiency, the safe upper limit of iodine intake during pregnancy remains
controversial. If an individual is exposed to high iodine levels, the synthesis of T4 and T3
will be acutely inhibited by a process known as the acute Wolff–Chaikoff effect [29].
In summary, there are contrasting recommendations for the upper limit of iodine intake.
The U.S. Institute of Medicine recommends an upper limit of 1100 μg dietary iodine daily in
pregnancy, while the World Health Organization (WHO) recommends an upper limit of 500
μg per day [21,30].
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2. Hypothyroidism and fertility
Thyroid function may be altered by serum thyroid antibodies, including serum anti-thyro‐
globulin antibodies (TgAb) and anti-thyroid peroxidase antibodies (TPOAb), particularly in
older women [31].
Several studies [32-39] indicate that elevated levels of anti-thyroid antibodies are present in
women three times more often than in men. This discordant predominance in thyroid auto‐
immunity could be associated with the X chromosome, which preserves some sex and im‐
mune-related genes responsible for immune tolerance [40]. Genetic defects of the X
chromosome (monosomy or structural abnormalities) could be responsible for increased and
altered immune-reactivity. In fact, patients with Turner’s syndrome [41] and those with a
higher rate of X chromosome monosomy in peripheral white blood cells [42] exhibit a higher
incidence of thyroid autoimmunity than karyotypically normal individuals. Similarly,
skewed X-chromosome inactivation leads to the escape of X-linked self-antigens from pre‐
sentation in thymus and a subsequent loss of T-cell tolerance. The result is an associated
higher risk of developing autoimmune thyroid diseases.
Self-tolerance is maintained by two mechanisms: central tolerance, which is performed by
thymus deletion of auto-reactive T cells during fetal life, and peripheral tolerance, whereby
those cells that escape central tolerance are inhibited to prevent them from triggering auto‐
immunity. It is well known that hormonal changes and trophoblastic immune-modulatory
molecules enable the tolerance of the fetal semi-allograft during pregnancy. Both cell-medi‐
ated and humoral immune responses are attenuated, shifting the immune response toward
the humoral with subsequent immune tolerance of the fetal tissues. It is for this reason that
during pregnancy, both TPOAb and TgAb concentrations decrease, reaching the lowest val‐
ues in the third trimester [43-48]. In puerperium, the immune response rapidly returns to
the pre-pregnancy state, potentially promoting or aggravating autoimmune thyroid disease
[43]. TPOAb concentrations rapidly increase and reach the maximum level at about 20
weeks after delivery [46-48]. Postpartum thyroiditis is a frequent complication, and 50% of
females with positive TPOAbs (TPOAb+) in early pregnancy develop this condition. The
clinical features of postpartum thyroiditis may arise within the first year after delivery as a
transient thyrotoxicosis and/or a transient hypothyroidism, but permanent hypothyroidism
develops in approximately one third of females [49].
Some analyses demonstrate that weakened immunosuppression in late pregnancy could
contribute to postpartum thyroid dysfunction. In fact, females with postpartum thyroiditis
exhibit increased secretion of IFN and IL-4 but lower median plasma cortisol concentrations
in the 36th week of gestation than do euthyroid females [50].
In nature, there is a particular phenomenon, fetal microchimerism, that is responsible for the
transfer of fetal cells to the maternal circulation during pregnancy. Several years after the
delivery, the chimeric cells can be detected in different maternal districts, including the pe‐
ripheral blood [51,52] and maternal tissues such as the thyroid, lung, skin, or lymph nodes
[53]. In puerperium, immunotolerance decreases, and consequently, the activation of the fe‐
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tal immune cells localized in the maternal thyroid gland can act as a trigger for autoimmune
thyroid disease. In support of this, the presence of fetal microchimeric cells is significantly
higher in autoimmune hypothyroidism than in the absence of autoimmune thyroid disease
[54-57]. However, the data are contradictory. Some studies demonstrate that heterozygotic
twins exhibit a significantly higher prevalence of Thyroid Antibodies (TAbs) compared to
monozygotic twins [58] and that euthyroid females with a previous pregnancy more fre‐
quently exhibit positive TPOAb compared to nulliparous females [59]. However, large pop‐
ulation-based studies have not confirmed the relationship between parity and autoimmune
thyroid disease. Consequently, the contribution of fetal microchimerism to the pathogenesis
of autoimmune thyroid disease remains to be elucidated [60-63].
Spontaneous pregnancy loss is an obstetrical complication occurring at less than 20 weeks of
gestation and has a prevalence ranging between 17% and 31% of all gestations [64,65]. Re‐
current pregnancy loss is defined as either two consecutive losses or three total spontaneous
losses and may occur in up to 1% of all pregnant women [66]. The individual risk depends
on several factors including maternal age, family history, environmental exposures [67], pa‐
rental chromosomal anomalies, immunologic derangements, uterine pathology, endocrine
dysfunction and medical co-morbidities [68]. Pregnancy loss may result in bleeding, infec‐
tions, pain and surgical procedures. Obviously, patients are strongly emotionally involved
in a negative pregnancy outcome. Endocrine disorders are important risk factors for sponta‐
neous pregnancy loss; patients with poorly controlled diabetes mellitus may have up to a
50% risk of loss [69], and thyroid dysfunction has also been associated with elevated rates of
pregnancy loss [70,71]. Stagnaro-Green and colleagues [72] published a prospective observa‐
tional study indicating that patients positive for thyroid antibodies (TPO and Tg) had a two-
fold increase in the risk of a pregnancy loss. Similarly, Iijima and colleagues [73] also
reported an association between spontaneous pregnancy loss and the presence of anti-mi‐
crosomal antibodies. In support of these studies, a meta-analysis [74] demonstrated a clear
association between thyroid antibodies and spontaneous abortion. The study also reported
that TAb+ women were slightly older and had slightly higher TSH levels than did antibody-
negative women. Negro and colleagues [75-76] performed a prospective, randomized inter‐
ventional trial of Levothyroxine (LT4) in euthyroid patients who were TPOAb+. The authors
reported a significantly decreased rate of pregnancy loss in the treated group, but their anal‐
yses were limited because the mean estimated gestational age of the patients commencing
LT4 therapy was 10 weeks, and all but one of the losses occurred at less than 11 weeks. In a
case–control study of Iravani and colleagues [77] and in the study of Kutteh et al. [78], pa‐
tients with primary recurrent pregnancy losses (three or more) had a higher prevalence of
anti-thyroid antibody. In the prospective observational study of Esplin and colleagues [79],
no difference in thyroid antibody positivity between patients with recurrent pregnancy loss
and healthy controls was observed. Other authors reported a higher rate of subsequent
pregnancy loss in patients with recurrent losses and thyroid antibody positivity [80]. In the
clinical trial by Rushworth and colleagues [81], there was no significant difference in live
birth rates between women with recurrent losses who were positive for anti-thyroid anti‐
bodies and those who were not.
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Additionally, the coexistence of more elements may create a synergic effect. The study by De
Carolis et al. demonstrated an apparent interaction between anti-phospholipid antibodies
and thyroid antibodies in the risk of recurrent pregnancy loss [82].
The data for an association between thyroid antibodies and recurrent pregnancy loss are less
robust than for sporadic loss. The results are also somewhat contradictory, and many trials
did not consider other potential causes of recurrent losses.
Recently,  Lazzarin  et  al.  [83]  performed  TRH  stimulation  (200  μg)  to  evaluate  thyroid
function in patients with recurrent miscarriages and anti-thyroid antibodies. The authors
determined that thyroid autoimmunity could be considered an indirect sign of mild thy‐
roid  dysfunction  and that  TRH stimulation  could  be  a  useful  tool  to  detect  subtle  thy‐
roid dysfunction.
Some authors have also established an 'iTSHa index' (TSH increase after TRH adjusted for
the levels of basal TSH), determining TSH serum levels at time 0 and 20 min after TRH stim‐
ulation in women with two or more miscarriages within the first 10 weeks of pregnancy.
This index is useful to identify women with recurrent miscarriages due to transient thyroid
dysfunction of early pregnancy. If validated, the index could be used for those patients with
no evidence of thyroid dysfunction and TSH levels within the low-normal reference range
who may nonetheless be at risk for recurrent abortions [84].
Some authors tried to analyze the possible use of intravenous immunoglobulin (IVIG) to
prevent recurrent pregnancy loss in women with anti-thyroid antibodies. Three small non‐
randomized case series have been published [85-87], and the live birth rates ranged from
80% to 95%. One study involved a comparison of a group of women who refused IVIG ther‐
apy (control group) with an IVG-treated group. A highly significant improvement in live
births was reported in the IVIG-treated cohort [86]. In one study, a higher rate of term deliv‐
ery was achieved by the LT4-treated group [87] compared to that of the IVIG group. In sum‐
mary, all three studies had serious methodological problems (small sample size,
heterogeneous patient populations, lack of or limited randomization, and differences in the
timing of the treatment). These are the limitations of the intervention trials with IVIG or LT4
in TAb+ women with recurrent abortions.
In consideration of these findings, the Guidelines of the American Thyroid Association for
the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum [76]
stress that there is insufficient evidence to recommend for or against screening all women
for anti-thyroid antibodies in the first trimester of pregnancy (Level I). Additionally, it is
stressed that, in euthyroid women with sporadic or recurrent abortions or in women under‐
going in vitro fertilization (IVF), there is insufficient evidence to recommend for or against
screening for anti-thyroid antibodies or treating in the first trimester of pregnancy with LT4
or IVIG (Level I). Similarly, in TAb+ euthyroid women during pregnancy, there is insuffi‐
cient evidence to recommend for or against LT4 therapy (Level I).
Some  authors  [88]  investigated  the  role  of  steroid  pretreatment  on  the  pregnancy  rate
and  pregnancy  outcomes  in  patients  positive  for  anti-thyroid  antibodies  who  were  un‐
dergoing  induction  of  ovulation  and  intrauterine  insemination  (IUI).  The  patients  were
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divided into 3  groups:  a  control  group of  infertile  women without  anti-thyroid autoim‐
munity and two groups of infertile women with anti-thyroid autoimmunity,  one treated
with  prednisone  (administered  orally  for  4  weeks  before  IUI)  and  the  other  receiving
placebo. Prophylactic therapy with steroids was associated with a significantly increased
rate of  pregnancy compared with placebo in infertile  women with anti-thyroid antibod‐
ies  undergoing  induction  of  ovulation  and  IUI,  although  the  miscarriage  rate  did  not
significantly differ among the groups.
Several studies reported an increased risk of pregnancy loss after assisted reproductive pro‐
cedures in women who were positive for anti-thyroid antibodies [89-91], whereas other au‐
thors have detected no association [92,93]. Additionally, patients undergoing IVF in the
presence of anti-thyroid antibodies exhibited an increased risk of pregnancy loss (meta-anal‐
ysis of four trials) [94]. Negro et al. [95] performed a prospective placebo–controlled inter‐
vention trial. No difference in pregnancy loss was observed when LT4 was used to treat
TPOAb+ women undergoing assisted reproduction technologies. The variable results high‐
light that there are a number of reasons for infertility or subfertility that may characterize
patients undergoing assisted reproductive procedures for infertility.
The guidelines of the American Thyroid Association for the Diagnosis and Management of
Thyroid Disease During Pregnancy and Postpartum [76] stress that in euthyroid TAb+ wom‐
en undergoing assisted reproductive technologies, there is insufficient evidence to recom‐
mend for or against LT4 therapy (Level I).
Some studies have analyzed the role of selenium in diminishing the TPOAb titers [96-101],
but at present, the risk to benefit comparison does not support routine selenium supplemen‐
tation for TPOAb+ women during pregnancy [76] (Level C).
3. Hypothyroidism and pregnancy
Several physiological changes take place in a pregnant woman that could cause an increased
incidence of hypothyroidism in the later stages of pregnancy in iodine-deficient women who
were euthyroid in the first trimester.
In pregnancy, the production of thyroxin (T4) and triiodothyronin (T3) rapidly increases by
50% together with a subsequent 50% increase in the daily iodine requirement. The fetal thy‐
roid begins to concentrate iodine to create triiodothyronin (T3) and thyroxin (T4) beginning
at 10-12 weeks of gestation, while TSH (fetal pituitary thyroid stimulating hormone) begins
to control thyroid function at approximately 20 weeks of gestation [102].
Maternal thyroxin crosses the placenta and maintains normal fetal thyroid function primari‐
ly in the early stages of gestation [103]. T3 is the active thyroid hormone produced after the
deiodination of T4 in different tissues, and both are largely bound to thyroid hormone bind‐
ing globulin (TBG). Rising maternal estradiol levels in early pregnancy causes increased liv‐
er sialyation and glycosylation of TBG [104,105] with a consequent decrease in the
peripheral metabolism of TBG [106,107]. This change creates an increased need for T3-T4
Current Topics in Hypothyroidism with Focus on Development8
production. During pregnancy, T4 and T3 are degraded at an increased rate to inactive iodo‐
thyronin (reverse T3) [108]. In addition, higher placental T4 transfer and hCG act as weak
stimulators of T3-T4 secretion and suppressors of TSH levels [109].
Additionally, the increase in the maternal glomerular filtration rate enhances the iodine re‐
quirements in pregnancy. In fact, iodine is passively excreted by the kidney, and increased
renal glomerular filtration results in increased losses of dietary iodine [110].
Under the influence of placental human chorionic gonadotropin (hCG), which also binds to
and stimulates the thyroidal TSH receptor [111], the levels of thyrotrophin (TSH) are de‐
creased throughout pregnancy, with the lower normal TSH level in the first trimester not
well defined and an upper limit of 2.5 mIU/L.
High estrogen levels in pregnant women are responsible for a 1.5-fold increase in serum thy‐
roxin binding globulin (TBG) concentrations. Therefore, there are higher levels of bound cir‐
culating total triiodothyronin (T3) and thyroxin (T4). In order to maintain free (or unbound)
thyroid hormone levels, thyroid hormone gland production is enhanced [112].
Some studies have demonstrated that total body T4 concentrations must increase 20%–50%
throughout gestation to maintain an euthyroid state [113,114], confirming that the increased
requirement for T4 (or exogenous LT4) occurs as early as 4–6 weeks of pregnancy [114] and
that such requirements gradually increase through 16–20 weeks of pregnancy with a subse‐
quent plateau until the time of delivery.
Primary maternal hypothyroidism is defined as the presence of elevated TSH concentrations
during gestation. There are rare exceptions to this definition, including a TSH-secreting pi‐
tuitary tumor, thyroid hormone resistance, and a few cases of central hypothyroidism with
biologically inactive TSH.
Pregnancy-specific reference ranges are necessary to define elevations in serum TSH during
pregnancy. When maternal TSH is elevated, measurements of serum FT4 concentrations are
necessary. The aim of such measurements is to classify the patient’s diagnosis as either overt
hypothyroidism (OH) or subclinical (SCH) hypothyroidism.
Patients exhibiting elevated TSH levels (>2.5 mIU/L) together with decreased FT4 concentra‐
tions and those with TSH levels of 10.0 mIU/L or above, irrespective of their FT4 levels, are
considered to have overt hypothyroidism.
Patients with a serum TSH value between 2.5 and 10 mIU/L and with a normal FT4 concen‐
tration are affected by subclinical hypothyroidism. The clinical definition is dependent upon
whether FT4 is within or below the trimester-specific FT4 reference range.
Data from a US population of iodine-sufficient women demonstrated that elevated serum
TSH levels are present in at least 2%–3% of apparently healthy, non-pregnant women of
childbearing age [115,116]. When thyroid function tests were performed, 0.3%–0.5% of those
women were diagnosed with OH and 2%–2.5% were diagnosed with SCH.
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When iodine intake is normal, Hashimoto’s thyroiditis is the most frequent cause of hypo‐
thyroidism; more than 80% of patients with OH and 50% of pregnant women with SCH ex‐
hibit thyroid autoantibodies [116].
Maternal and fetal effects of hypothyroidism have been well studied, and the results allow
for clinical recommendations for OH but not for SCH. There is a strict association between
overt maternal hypothyroidism and adverse pregnancy outcomes, particularly if this condi‐
tion arises early in pregnancy [116]. Some of these complications include preeclampsia,
eclampsia, pregnancy-induced hypertension, low birth weight [117], preterm birth [118,119],
breech delivery [120], placental abruption, infant respiratory distress syndrome, spontane‐
ous abortion [115,121], perinatal death [122] and fetal neurocognitive development [123,124].
In reproductive aged women, the prevalence of subclinical hypothyroidism is about 0.5-5%
[125]. It is well established that thyroid hormone is essential for fetal brain development and
maturation, explaining why the maternal transfer of thyroid hormone is essential, especially
during the first trimester of pregnancy. Children born to women who were inadequately
treated for subclinical hypothyroidism exhibit impaired mental development compared to
those born to women well-treated [123], but it is not well established whether the impaired
mental development is due to the thyroid hormone deficiency itself or to the subsequent ob‐
stetric complications [126].
Although data regarding SCH are less complete than those regarding OH, Negro and collea‐
gues [127] found that SCH increases the risk of pregnancy complications in anti-thyroid per‐
oxidase antibody positive (TPOAb+) pregnant women. Their trial screened a low-risk
pregnant population with SCH for TPOAb+ and TSH >2.5 mIU/ L. Half of the patients with
this combination underwent LT4 treatment to normalize serum TSH, and the other half
served as the control group. The results confirmed a significant reduction in the combined
endpoint of pregnancy complications. Further, Negro et al. [128] noticed that TPOAb- (nega‐
tive) women with TSH levels between 2.5 and 5.0 mIU/L exhibited a higher miscarriage rate
compared with pregnant women with TSH levels below 2.5 mIU/L.
These prospective data are supported by previous retrospective data published by Casey
and colleagues [115], who identified a two- to three-fold increased risk of pregnancy-related
complications in untreated women with SCH. However, some published data reached con‐
flicting conclusions; Cleary-Goldman et al. [129] reported no adverse effects in SCH preg‐
nant women (detected in the first and second trimester). The limitation of this study is that
the analysis was performed with only a selected subgroup of the entire study cohort, with a
mean gestational age of screening between 10.5 and 14 weeks of gestation.
Recently, Ashoor et al. [130] evaluated TSH and FT4 levels in 202 singleton pregnancies at
11–13 weeks that subsequently resulted in miscarriage or fetal death. The results demon‐
strated that these patients had increased TSH levels above the 97.5th percentile and FT4 lev‐
els below the 2.5th percentile compared to the 4318 normal pregnancies of the control group.
This trial suggests that SCH is associated with an increased risk of adverse pregnancy out‐
comes, although the detrimental effect of SCH on fetal neurocognitive development is less
clear. The case-control study by Haddow et al. [123] demonstrated a reduction in the intelli‐
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gence quotient (IQ) among children born to untreated hypothyroid women when compared
to the children of pregnant euthyroid controls. In summary, adverse fetal neurocognitive de‐
velopment is biologically plausible [131], though not clearly demonstrated, in SCH. For this
reason, clinicians should consider these potential increased risks associated with SCH and
could consider LT4 treatment for these patients.
The guidelines of the American Thyroid Association for the Diagnosis and Management of
Thyroid Disease During Pregnancy and Postpartum [76] note that SCH has been associated
with adverse maternal and fetal outcomes. However, due to the lack of randomized control‐
led trials, there is insufficient evidence to recommend for or against universal LT4 treatment
in TAb- pregnant women with SCH (Level I). The aim of LT4 treatment is to normalize ma‐
ternal serum TSH values within a trimester-specific pregnancy reference range (Level A).
Numerous  retrospective  and  case-controlled  studies  confirm  the  detrimental  effects  of
OH on pregnancy and fetal  health,  and the available data confirm the benefits  of  treat‐
ing OH during pregnancy. This recommendation is useful for women with TSH concen‐
trations  above the trimester-specific  reference interval  and with decreased FT4 levels  as
well  as  for  all  women  with  TSH  concentrations  above  10.0  mIU/L,  irrespective  of  FT4
levels (Level A). In addition, women positive for TPOAb and affected by SCH should be
treated with LT4 (Level B).
The recommended treatment for maternal hypothyroidism is oral LT4. It is strongly rec‐
ommended  that  other  thyroid  preparations,  such  as  T3  or  desiccated  thyroid,  not  be
used (Level A).
In the literature, the reference range for TSH is well established to be lower in pregnan‐
cy;  both  the  lower  and the  upper  limit  of  serum TSH are  decreased  by  approximately
0.1–0.2  mIU/L and 1.0  mIU/L,  respectively,  compared to  the  usual  TSH reference  inter‐
val of 0.4–4.0 mIU/L in non-pregnant women. Serum TSH and its reference range gradu‐
ally  rise  throughout  the  pregnancy,  but  this  interval  remains  lower  than  in  non-
pregnant  women  [122,132].  Several  confounding  factors  (e.g.,  diet),  can  influence  TSH
values in women with no thyroid pathologies.
In multiple pregnancies, the higher hCG level is responsible for lower TSH serum concentra‐
tions [133]. Therefore, some authors have suggested specific TSH ranges in pregnancy of
0.1-2.5 mUI/L for the first trimester, 0.2-0.3 mUI/L for the second trimester, and 0.3-3.0 for
the third trimester [76,134].
As previously defined, overt hypothyroidism is characterized by elevated serum TSH levels
with low serum FT4 levels, whereas subclinical hypothyroidism is characterized by elevated
serum TSH levels with normal serum FT4 levels.
Isolated hypothyroxinemia is characterized by normal maternal TSH concentrations and
FT4 concentrations in the lower 5th or 10th percentile of the reference range. It is controver‐
sial whether isolated hypothyroxinemia causes any adverse effects on the developing fetus.
In the study of Pop and colleagues [135], psychomotor test scores among offspring born to
women with normal serum TSH values and FT4 indices in the lowest 10th percentile were
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decreased compared to controls. In the analyses of Li et al. [124], mothers who experienced
either hypothyroidism or isolated hypothyroxinemia during the first trimester gave birth to
children with lower IQ scores. However, these studies have methodological limits.
In their prospective, Henrichs and colleagues conducted a prospective nonrandomized in‐
vestigation on isolated maternal hypothyroxinemia [136] and reported that a 1.5- to 2-fold
increased risk for adverse events (children at 3 years of age) in communication development
was associated with maternal FT4 levels in the lower 5th and 10th percentiles. To date, there
are no recommendations for isolated hypothyroxinemia, and consequently, isolated hypo‐
thyroxinemia should not be treated during pregnancy (Level C).
In the first trimester of pregnancy, approximately 10% to 20% of all pregnant women are
TPO- or Tg-antibody positive and euthyroid. In addition, approximately 16% of the women
who are euthyroid and positive for TPO or Tg antibodies in the first trimester will develop a
TSH that exceeds 4.0 mIU/L by the third trimester, and approximately 33%–50% of women
positive for TPO or Tg antibodies in the first trimester will develop postpartum thyroiditis.
These data could be the result of a direct effect of the antibodies or an indirect marker of an
autoimmune syndrome or the thyroid functional reserve [106].
Another important aspect to consider is the significant ethnic difference in serum TSH con‐
centrations. In fact, pregnant women of Moroccan, Turkish, or Surinamese descent residing
in The Netherlands exhibit TSH values 0.2–0.3 mIU/L lower than Dutch women throughout
pregnancy [137]. Black and Asian women exhibit TSH values that are on average 0.4 mIU/L
lower than those in white women; these differences persist during pregnancy [138,139].
There are different methods for the analysis of TSH levels, and TSH ranges vary slightly de‐
pending on the method used [140]. However, trimester-specific reference ranges for TSH
should be applied (Level B). If they are not available in the laboratory, the following refer‐
ence ranges are recommended: first trimester, 0.1–2.5 mIU/L; second trimester, 0.2–3.0
mIU/L; third trimester, 0.3–3.0 mIU/L (Level I).
Total T4-T3 values or the ratio of Total T4 to TBG are useful to calculate the normal ranges
for the FT4 index, but there are not trimester-specific reference intervals for the FT4 index of
a reference population. To assess serum FT4 during pregnancy, the optimal method is meas‐
urement of T4 in the dialysate or ultrafiltrate of serum samples employing on-line extrac‐
tion/liquid chromatography/tandem mass spectrometry (LC/MS/ MS) (Level A). If not
available, clinicians should use whichever measure or estimate of FT4 is available in their
laboratory and should be aware of the limitations of each method. However, serum TSH re‐
mains the most accurate method to study thyroid status during pregnancy (Level A).
In the presence of high concentrations of bound T4, it is difficult to measure the levels of FT4
due to the abnormal binding-protein states such as pregnancy. Therefore, method-specific
and trimester-specific reference ranges of serum FT4 are required (Level B).
The guidelines of the American Thyroid Association for the Diagnosis and Management of
Thyroid Disease During Pregnancy and Postpartum [76] stress that, although not prospec‐
tively studied, the approach of not initially treating women with SCH in pregnancy should
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involve monitoring the women for possible progression to OH by measuring serum TSH
and FT4 levels approximately every four weeks until 16– 20 weeks gestation and at least
once between 26 and 32 weeks gestation (Level I).
These considerations are important to make the therapy adjustments in affected women
once pregnant and to plan the follow-up intervals for TSH in treated patients. If necessary,
LT4 adjustments should be made as soon as possible after pregnancy is confirmed; it is im‐
portant to stress that between 50% and 85% [113,114,141] of hypothyroid women treated
with exogenous LT4 require increased doses during pregnancy. This need for adjustment is
related to the etiology of hypothyroidism itself.
The clinical recommendation is that treated hypothyroid patients (receiving LT4) and newly
pregnant women should independently increase their dose of LT4 by 25%–30% upon a
missed menstrual cycle or positive home pregnancy test. Pregnant women could accomplish
this adjustment by increasing LT4 from once daily dosing to a total of nine doses per week
(29% increase). (Level B)
Obviously, the aim of treatment is to optimize a woman’s preconception thyroid status. Dif‐
ferent studies have analyzed the possible TSH cutoff values for women planning a pregnan‐
cy, but other factors, like maternal estrogen levels, can influence the LT4 augmentation
necessary to maintain a euthyroid state during pregnancy.
The guidelines of the American Thyroid Association for the Diagnosis and Management of
Thyroid Disease During Pregnancy and Postpartum [76] indicate that preconception serum
TSH values <2.5 mIU/L are an indirect marker of a good thyroid state in treated hypothyroid
patients (receiving LT4) who are planning a pregnancy. Similarly, TSH values <1.5 mIU/L
will likely further reduce the risk of mild hypothyroidism in early pregnancy by reducing
the risk of TSH elevation during the first trimester. However, no differences in pregnancy
outcomes have been demonstrated by this approach (Level B).
In these patients, maternal serum TSH levels should be monitored approximately every 4
weeks during the first half of pregnancy. Indeed, further LT4 dose adjustments are often re‐
quired (Level B), and maternal TSH should be checked at least once between 26 and 32
weeks gestation (Level I).
Following delivery, LT4 should be reduced to the patient’s preconception dose. Additional
TSH testing should be performed at approximately 6 weeks postpartum (Level B).
However, women with Hashimoto’s thyroiditis could need an increased LT4 dose in the
postpartum period [142] compared to their prepartum dose.
Pregnant women treated and monitored appropriately should not require any additional
tests; there are no other maternal and fetal recommended tests in the absence of other preg‐
nancy complications (Level A).
Some studies [75,119] confirmed an increased requirement for thyroid hormone during ges‐
tation in women who are TAb+. Both OH and SCH may occur during the stress of pregnan‐
cy as a result of compromised thyroid function. This situation usually occurs later in
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gestation because in the first part of pregnancy, the residual thyroid function can act as a
buffer.
Because the risk of hypothyroidism in women who are TAb+ is increased, a higher level of
surveillance, by evaluating TSH levels approximately every 4–6 weeks during pregnancy, is
required [114].
Fetal status in pregnant women under chronic therapy with levothyroxine has been studied
by performing computerized FHR (fetal heart rate) analyses (cCTG). This is a sensible and
reproducible method to identify pregnancies with a pathological neonatal outcome. Publish‐
ed data [143] suggest that maternal hypothyroidism and levothyroxine treatment have an
important influence on FHR, and cCTG analyses are a sensible means of revealing and
studying these conditions. In their analyses, the authors stressed that fetal reactivity, ex‐
pressed by reduced baseline FHR and reduced fetal movements, remained suppressed in
well-treated hypothyroid pregnant women who became euthyroid, suggesting that this sup‐
pression could be due to the influence of a chronic hypothyroid state.
4. Hypothyroidism and contraception
In the literature, there is little evidence about the influence of contraceptives on thyroid
function. The study of Ågren et al. [144] analyzes the effects of two monophasic combined
oral contraceptives (nomegestrol acetate/17 beta estradiol or levonorgestrel/ethinylestradiol)
on androgen levels, endocrine function and sex hormone-binding globulin (SHBG) levels in
121 healthy women. The authors found that the levels of thyroxin-binding globulin (TBG),
together with total cortisol and corticosteroid-binding globulin (CBG) levels, increased in
both groups, with a significantly greater increase observed in the group with levonorgestrel/
ethinylestradiol. Thyroid-stimulating hormone (TSH) and free thyroxin (T4) remained unal‐
tered from their baseline values, and no difference was observed between the groups. If TBG
rises, clearance of tri-iodothyronin (T3) and T4 is reduced, thereby increasing total T3 and
T4 levels. However, as described, estroprogestin oral contraceptives have little or no effect
on physiologically active free fractions of thyroid hormones. In fact, in the same study, no
significant changes in free T4 or in TSH levels were observed in either group after six
months of treatment, in agreement with other studies [145-147].
In summary, oral contraceptives can be responsible for increasing TBG without a significant
influence on thyroid-stimulating hormone (TSH) and free thyroxin (T4) levels.
5. Conclusions
A euthyroid state is the goal for women affected by hypothyroidism; the normalization of
thyroid markers is necessary for metabolic, endocrine and sexual improvement. Obviously,
the presence of anti-thyroid antibodies signifies an underlying state of imbalanced patient-
specific autoimmunity that can be addressed with effective treatments.
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In pregnant women, treatment of hypothyroidism is not associated with adverse perinatal
outcomes [148], and although it is not well known how levothyroxine treatment during
pregnancy improves the neurological development of the offspring, clinical practice guide‐
lines recommend this therapy [148, 149].
The choice of cut-off values for TSH in the three trimesters of pregnancy has important im‐
plications both for the interpretation of the literature and for the critical impact of the clini‐
cal diagnosis of hypothyroidism.
Overt hypothyroidism and overt hyperthyroidism have a deleterious impact on pregnancy.
However, questions about hypothyroidism and pregnancy remain, including those regard‐
ing the impact of subclinical hypothyroidism on pregnancy; the impact of TAbs on miscar‐
riage, preterm delivery and puerperal thyroiditis in euthyroid women; and if, when and
who should be screened for anti-thyroid hormones during pregnancy. For this latter ques‐
tion, very recent papers addressed the problem with conflicting results: Lazarus et al. [150]
conducted a randomized trial in which antenatal screening and maternal treatment for hy‐
pothyroidism did not result in improved cognitive function in three-year-old children (pos‐
sible limitations of this study are that levothyroxine therapy was performed too late in
gestation and that about 24% of the women were lost to follow-up) while Dosiou et al. [151]
stressed that universal screening of pregnant women in the first trimester for autoimmune
thyroid disease is cost-effective without the calculation of a possible decrease of the off‐
spring cognitive function. The question remains open.
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